, Edith Said 32, 33 , Meropi Toumba 34, 35 , Zeynep Tümer 20 , Gerhard Binder 36 , Thomas Eggermann 18 , Madeleine D. Harbison 37 , I. Karen Temple 5, 6 , Deborah J. G. Mackay 5 and Irène Netchine [2] [3] [4] Abstract | This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver-Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.
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Methods 41 task force members from 16 countries, chosen for their publication record and expertise in SRS, collaborated to develop this consensus statement. They included paediatric endocrinologists, clinical geneticists, molecular geneticists, a gastroenterologist and five non-voting representatives from a parent support group. Participants included representatives nominated by the council and clinical practice committees from four international paediatric endocrine societies. All participants signed a conflict of interest declaration, and the consensus was supported by academic funding, without pharmaceutical support. A Delphi-like consensus methodology was adopted 11 . A comprehensive literature search was conducted using PubMed and the search terms "Silver Russell syndrome" and "Russell Silver syndrome". Additional relevant articles on SGA, differential diagnoses and growth hormone (GH) were also identified by PubMed searches when supplementary information was necessary. A comprehensive review of >600 articles formed the basis of discussion by three working groups. These groups focused on clinical diagnosis (working group 1: E.L.W., J.S., K.H.C., M.E., R.P.D., P.G.M., T.O., E.S., M.T. Preparations for the consensus took place over 10 months, including two preparatory meetings and regular teleconference discussions between the working group members. At the final consensus meeting, propositions and recommendations were considered by participants and discussed in plenary sessions, enabling reformulation of the recommendations if necessary. Where published data were unavailable or insufficient, experts' clinical experiences and opinions were considered. Finally, all experts voted on the recommendations of each working group using the following system:
A. Evidence or general agreement allow full agreement with the recommendation B. Evidence or general agreement are in favour of the recommendation C. Evidence or general agreement are weak for the recommendation D. There is not enough evidence or general agreement to agree with the recommendation Depending on the proportion of votes received, the strength of the recommendation was recorded as follows: + 26-49% of the votes ++ 50-69% of the votes +++ ≥70% of the votes Clinical diagnosis SRS is currently a clinical diagnosis based on a combination of characteristic features. Molecular testing can confirm the diagnosis in around 60% of patients 4 . Molecular testing enables stratification of patients with SRS into subgroups, which can lead to more tailored management. However, molecular investigations are negative in a notable proportion of patients with characteristic clinical features of SRS. For these patients, an established clinical diagnosis enables access to appropriate support groups, treatment (including GH) and further research into the underlying incidence, natural history and aetiology of the SRS phenotype.
However, the diagnosis of SRS can be difficult, as the condition varies widely in severity among affected individuals and many of its features are nonspecific [4] [5] [6] . Until now, no consensus has been reached on the clinical definition of SRS. Historically, this lack of consensus has probably led to underdiagnosis and overdiagnosis, particularly by clinicians unfamiliar with SRS.
Several clinical scoring systems for SRS have been proposed, which reflects the challenge in reaching a confident diagnosis 4, 5, [12] [13] [14] [15] . All the systems use similar criteria, but vary in the number and definition of diagnostic features required for diagnosis. The relative sensitivity and specificity of these scoring systems have been compared in patients with confirmed molecular diagnoses 14, 15 .
Netchine-Harbison clinical scoring system
The Netchine-Harbison clinical scoring system (NH-CSS; TABLE 1), which was proposed by Azzi and colleagues in 2015, 15 is the only scoring system for the diagnosis of SRS that was developed using prospective data. Four of the six criteria are objective; protruding forehead and feeding difficulties remain subjective, but clear clinical definitions are given. Using the same cohort, the NH-CSS proved more sensitive (98%) than previous systems 4, 14 . The NH-CSS also had the highest negative predictive value (89%), which gives a high degree of confidence that patients who have less than four of the six clinical criteria for diagnosis are truly unaffected by SRS. The system is easy to use in a busy clinical setting. The NH-CSS is also flexible enough to use even if data are incomplete, which is important as the diagnosis is often made in infancy, before information about postnatal growth and BMI is available.
Box 1 | Definitions
Small for gestational age (SGA) Weight and/or length less than −2 SDS for gestational age at birth, based on accurate anthropometry at birth (including weight, length and head circumference) and reference data from a relevant population 106 .
Intrauterine growth retardation
Also known as intrauterine growth restriction, this diagnosis is based on at least two ultrasonography measurements at least 2 weeks apart, with fetal weight below the 10th percentile for gestational age. Intrauterine growth retardation might or might not result in a baby born SGA 161 .
Silver-Russell syndrome (SRS)
A distinct syndromic growth disorder in which prenatal and postnatal growth failure are associated with other characteristic features, including relative macrocephaly at birth, protruding forehead in early life, body asymmetry and substantial feeding difficulties. Almost all children with SRS are born SGA. Postnatal catch-up growth is not seen in the majority of children with SRS.
Similarly to other clinical scoring systems, the NH-CSS has a low specificity (36%) 15 , which could result in false positive results when the diagnosis is just based on clinical findings. Relative macrocephaly at birth (defined as a head circumference at birth ≥1.5 SDS above birth weight and/or length SDS) and protruding forehead are the two features in the NH-CSS that best distinguish SRS from non-SRS SGA (see Supplementary information S1 (table)) 4, [15] [16] [17] [18] . To maintain confidence in the clinical diagnosis if all molecular testing is normal, we recommend that only patients scoring at least four of six criteria, including both prominent forehead and relative macrocephaly, should be diagnosed as 'clinical SRS' (previously known as 'idiopathic SRS'); see the flow diagram for investigation and diagnosis of SRS (FIG. 1) .
Diagnosis in late childhood or adulthood
All scoring systems for SRS have been developed and validated in paediatric cohorts. However, an increasing number of adults with a historical diagnosis of SRS are being seen by clinicians, particularly regarding their concerns about passing the condition on to their offspring (personal experience of working groups 1 and 3). In these patients, a clinical diagnosis is frequently challenged by lack of early growth data. An attempt should be made to obtain photographs of the individual aged 1-3 years, especially of the face in profile, as well as measurements at birth and in the first 2 years. No current evidence exists to support an alternative approach to diagnosis in adults.
Additional clinical features
In addition to the clinical features in the NH-CSS, several others are recognized in association with SRS, as shown in TABLE 2 and Supplementary information S1 (table) . These characteristics are not specific to SRS, and might be present in children born SGA who do not have SRS, but at a lower frequency than in patients with SRS. However, a few features occur at a much higher rate in children with SRS than in those with SGA 4, 15, 16 . These features include low muscle mass, crowded or irregular teeth, micrognathia, down-turned mouth, clinodactyly and excessive sweating. (FIG. 1) , based on the NH-CSS, should be adopted for the investigation and diagnosis of SRS. (A++) 1.3 In children aged <2 years, adolescents and adults, a reduced threshold for molecular testing might be required due to missing data. (A++)
Molecular diagnosis

Investigation and diagnosis
A positive molecular test result provides useful confirmation of the clinical diagnosis (FIG. 1) . This result also enables stratification into a specific molecular subgroup that, in turn, can help guide appropriate management. However, many patients are referred for molecular testing with few, or atypical, features of SRS, which leads to low diagnostic yields and incurs unnecessary expense 19 . We, therefore, recommend the use of the flow chart in FIG. 1 to aid in the investigation and diagnosis of SRS.
Some patients, particularly those with upd(7)mat, have fewer typical clinical features of SRS than patients with 11p15 LOM 4, 5, 13, 16, 20, 21 . In the cohort reported by Azzi and co-workers 15 , one of the nine patients scoring three of six criteria (and therefore predicted 'unlikely to have SRS') had upd(7)mat. The threshold recommended in FIG. 1 for molecular testing (≥3 of six criteria) is, therefore, lower than that needed for a clinical diagnosis of SRS (≥4 of six criteria).
Conversely, in the same cohort, no positive molecular diagnoses were made in patients scoring less than three of six criteria 15 . Other studies have also excluded 11p15 LOM and upd(7)mat in patients born SGA with postnatal growth retardation but without additional features of SRS 4, 10, 22 . We, therefore, do not recommend testing for SRS in patients scoring less than three of six criteria. Of note, a small number of patients with body asymmetry have been reported to have 11p15 LOM 20, 21, 23 . These patients would score fewer than three of six criteria, which is insufficient to justify a clinical diagnosis of SRS in these patients.
Chromosome 11p15
Both SRS and the overgrowth condition BeckwithWiedemann syndrome are associated with molecular abnormalities of chromosome 11p15.5, which contains two imprinted domains (FIG. 2) . Imprinting of the telomeric domain, which is strongly implicated in SRS 24, 25 , is controlled by the paternally methylated imprinting control region H19/IGF2 IG-DMR (H19/IGF2 intergenic differentially methylated region, previously known as IC1, ICR1 and H19 DMR). The centromeric domain contains the maternally expressed growth repressor CDKN1C; the imprinting of this gene is controlled by the maternally methylated imprinting control region KCNQ1OT1 TSS-DMR (previously known as IC2, ICR2, LIT1 or KvDMR1). FIGURE 3 summarises the more common molecular changes at chromosome 11p15 associated with SRS. Hypomethylation of the H19/IGF2 IG-DMR results in reduced paternal IGF2 expression and increased maternal H19 expression, which leads to growth restriction 9 . Numerous copy number variants (CNVs) involving the 11p15.5 region have been reported; the phenotype is dependent on CNV size, location and parental origin 24, 26 (see Supplementary information S2 (table)).
Molecular testing must robustly and accurately measure DNA methylation of CpG dinucleotides at H19/IGF2 IG-DMR 27 . Assays involve either bisulfite analysis [28] [29] [30] or enzymatic methods, such as methylation-specific multiplex ligation-mediated PCR amplification (MS-MLPA) or Southern blotting 9, 31 . The most common test in diagnostic use is MS-MLPA, which is economical on DNA, cost-effective and enables parallel analysis of copy number and DNA methylation 31, 32 . Hypomethylation of H19/IGF2 IG-DMR is frequently incomplete and low levels of hypomethylation might elude detection. Methylation patterns might vary between different tissues and cells (leucocytes, samples from a buccal swab and skin fibroblasts) 21, 33, 34 and could explain cases of a negative molecular diagnosis using a blood sample.
Although copy number change can be detected by MS-MLPA, additional array analysis is useful for characterizing the size and gene content of any CNV identified.
Chromosome 7
Of individuals with SRS, ≤10% have upd(7)mat 35, 36 . The SRS phenotype of upd (7)mat is thought to result from altered expression of an imprinted growth-regulatory gene (or genes) 37 . In addition, the duplication of pre-existing pathogenic mutations by isodisomy can lead to the clinical expression of recessive disorders (such as cystic fibrosis) in patients with upd(7)mat [38] [39] [40] . Candidate SRS regions have been suggested through identification of patients with segmental upd(7)mat or CNVs (see Supplementary information S3 (table)); the primary candidate SRS genes on chromosome 7 are currently GRB10 (7p12.1) and MEST (7q32) [41] [42] [43] [44] [45] [46] [47] [48] . Microsatellite analysis was the first diagnostic test for upd(7)mat 35, 36 ; however, this analysis cannot detect imprinting defects (epimutations) and requires DNA from at least one parent. DNA methylation analysis, including at least the imprinting control regions GRB10 alt-TSS-DMR and MEST alt-TSS-DMR, can identify upd(7)mat, epimutations, CNVs and segmental or whole-chromosome variations. DNA methylation analysis, for example by MS-MLPA, is economical on DNA, cost-effective and compatible with parallel analysis of 11p15 (REFS 30, 49, 50) .
Additional testing
If testing of both 11p15 and chromosome 7 is negative, additional molecular testing can be considered.
CNVs. Over 30 different pathogenic CNVs have been described in patients with suspected SRS 15, [51] [52] [53] . Patients with these CNVs usually have more severe developmental delay and/or intellectual disability than is typically seen in SRS 52, 53 . Some patients fulfil the NH-CSS for diagnosis; others either do not meet the NH-CSS criteria, or insufficient data are given to use the criteria for their assessment. Although features of SRS can be present in individuals with a pathogenic CNV, clinical diagnosis of SRS is not helpful in these cases and management needs to be tailored specifically to the phenotypic consequences of the individual CNV.
While either array comparative genomic hybridization or single nucleotide polymorphism array can be used to detect CNVs, single nucleotide polymorphism array can also detect regions of segmental isodisomy 54 . 15, 57, 58 . However, in a study published in 2015, none of eight patients with upd(20)mat had relative macrocephaly or asymmetry 59 , two important criteria of the NH-CSS, which means that these patients might have eluded formal clinical diagnosis of SRS.
CDKN1C and IGF2 mutations. CDKN1C and IGF2 are the coding genes on chromosome 11p15 that are responsible for the growth anomalies in SRS and BeckwithWiedemann syndrome. Maternally transmitted SRS was described in a four-generation family with a CDKN1C gain-of-function mutation 60 , and paternally transmitted SRS in a family with an IGF2 loss-of-function mutation 61 . However, no additional mutations have been reported to date in sporadic or familial cases of SRS 60, 62, 63 . Sequence analysis of either gene might be considered, particularly in familial cases of SRS where the inheritance pattern is consistent; however, coding variants in these genes are rare 60, 62, 63 .
Multi-locus imprinting disturbance. A significant proportion (15-38%) of individuals with 11p15 LOM have multi-locus imprinting disturbance (MLID) 33, 57, [64] [65] [66] . High-density methylation arrays have revealed methylation changes involving both (maternally and paternally) imprinted and non-imprinted loci 67, 68 . However, despite welcome advances in genome-wide methylation screening 67, 69, 70 , standardization is required to ensure accurate description of MLID and comparison between cohorts.
The effect of MLID on clinical phenotype remains unclear. No difference in growth parameters was found at birth or at 2 years of age between patients with 11p15 LOM with and without MLID 64 . Although developmental delay and congenital anomalies were reported in patients with MLID, this finding might have been affected by ascertainment bias 57 . In principle, MLID might be caused by trans-acting genetic mutations that affect the acquisition or maintenance of imprints, but in practice, very few have been identified 71, 72 . . Less commonly, maternal duplication of the centromeric or both domains results in growth retardation due to increased dosage of CDKN1C; however, smaller copy number variants should be classified with caution due to the complex regulation of the region 27 . Rare familial cases have been associated with a maternal CDKN1C gain-of-function mutation (green cross) 60 or a paternal IGF2 loss-of-function mutation (red cross) upd (7)mat 15, 20 . Neurocognitive problems are more frequent in patients with upd(7)mat than in those with 11p15 LOM or clinical SRS 15, 16, 20 (see later section on neurocognitive problems).
Patients with 11p15 duplication encompassing H19/ IGF2 IG-DMR and KCNQ1OT1 TSS-DMR have an SRS phenotype, but usually without asymmetry and with an increased likelihood of developmental delay 53 . Of 15 patients reported to have a 11p15 duplication encompassing H19/IGF2 IG-DMR and KCNQ1OT1 TSS-DMR, four were noted to have hearing loss 74 .
Differential diagnosis
The differential diagnosis of children with short stature of prenatal onset includes many syndromic diagnoses and chromosomal rearrangements 75 (TABLES 3,4).
Particular features should prompt consideration of diagnoses other than SRS. These include relative microcephaly (head circumference SDS below height and weight SDS), notable global developmental delay or intellectual disability (without a related explanation such as documented hypoglycaemia), absence of severe feeding difficulties and/or the presence of additional congenital anomalies, facial dysmorphism or other features atypical of SRS. Disproportionate short stature is suggestive of skeletal dysplasia. Photosensitive skin rash or recurrent bronchopulmonary infections should prompt investigation for chromosome breakage disorders. As SRS is generally sporadic, a family history of growth failure and/or consanguinity might suggest an alternative underlying diagnosis 76 . The clinical features of the most important and/or likely differential diagnoses are summarized in TABLES 3, 4. A correct diagnosis can have extremely important implications for management. Response to GH treatment, if given, varies depending on the underlying syndromic diagnosis. For instance, GH treatment is contraindicated in patients with chromosome breakage disorders, such as Bloom syndrome, due to the associated risk of malignancy 77 . GH treatment in patients with SHORT syndrome has been reported to precipitate insulin resistance and subsequent type 2 diabetes mellitus 78 . An incorrect diagnosis of SRS leading to the recommendation of GH treatment could, therefore, have adverse consequences in these patients.
Three patients (one with no history of fractures) have been reported with clinical features of SRS but a molecular diagnosis of osteogenesis imperfecta, with a COL1A1 mutation 79, 80 . Both SRS and osteogenesis imperfecta can cause prenatal onset of growth failure, relative macrocephaly, large fontanelle, blue sclerae and body asymmetry. Both diagnoses should, therefore, be considered in patients with features overlapping both conditions. . Over time, progressive failure to thrive can result in a calorie-related length deficit 4, 15, 82 . Feeding difficulties and failure to thrive are considerably more frequent in patients with SRS than in children with SGA but not SRS 4, 17 . Failure to thrive in children with SRS is probably due to a combination of factors, including feeding difficulties (poor appetite, oromotor issues and the resulting low caloric intake) as well as functional and structural gastrointestinal problems. Digestive problems or malnutrition occur in over 70% of patients with SRS 82 , including severe gastrooesophageal reflux in 55%, which often results in persistent vomiting after the age of 1 year. Constipation is also common, particularly after age 2 years 82 . Cyproheptadine used as an appetite stimulant improves weight gain in other paediatric conditions 83, 84 ; however, specific studies of its use in SRS are needed before it can be recommended in these patients.
Recommendations
The main therapeutic goals for the first 2 years of life in patients with SRS are nutritional support, prevention of hypoglycaemia and recovery of any calorie-related length or height deficit, which should be addressed before initiation of GH therapy (see following sections on prevention of hypoglycaemia and GH therapy). However, careful monitoring is needed, especially during nonvolitional feeding, because rapid catch-up weight gain in children born SGA has been associated with an increased risk of metabolic and cardiovascular disease in later life 85 . Children with SRS have an abnormal body composition with low muscle mass, and are typically light for their length or height 3, 15, 86, 87 . From our experience, the target for healthy nutritional status is narrow, and is dependent on individual innate muscle mass and even slight overnourishment (for example, weight >90% of ideal weight for length or height) can rapidly increase relative fat mass. Suggested targets for children aged 2-4 years preparing for GH therapy are: weight 75-85% of the 50th centile weight for length or height and/or BMI 12-14 kg/m 2 , using height measurements on the longer side if notable leg length discrepancy is found (see following section on GH therapy). A weight below 70% of the ideal weight for length or height compromises growth velocity, despite GH treatment. For children >4 years old, the optimal target BMI will depend on their muscle mass. Two groups of patients are exceptions to this observation. Firstly, in patients with 11p15 LOM who have a very low muscle mass and considerable body asymmetry, a lower BMI might be adequate (11-12 kg/m 2 ). Secondly, for patients with upd(7)mat with near normal muscle mass, a higher BMI might be acceptable (14-15 kg/m 2 ). 
Prevention of hypoglycaemia
Young children with SRS, particularly under age 5 years, have low muscle and liver mass, a disproportionately large brain-for-body size and feeding difficulties, all of which increase their risk of fasting hypoglycaemia and its potential neurocognitive consequences. The incidence of hypoglycaemia in these children is approximately 27% 20 , with a high frequency of spontaneous, asymptomatic nocturnal hypoglycaemia 89 . Monitoring of levels of urinary ketones is usually effective in pre-empting hypoglycaemia related to fasting, activity or illness. This measurement can be used to determine the 'safe fasting time' for a child, which will change with age. Night time hypoglycaemia can be prevented by adding either high molecular weight glucose polymer (for infants under 10 months) or uncooked corn starch (for older infants and children particularly at risk) to the last evening feed. Dental hygiene is important as complex carbohydrates can promote cavities 90 . Severe, non-fasting and non-ketotic hypoglycaemia should always be identified and investigated further.
For episodes of preoperative fasting or febrile illness, intravenous glucose (10% dextrose) might be required. Children with SRS might need longer periods of gut rest than children with SGA but not SRS before oral or enteral feeding because of their gut dysmotility and intrinsic feeding defects. Before discharge, it is advisable to achieve an absence of ketonuria following at least 12 h of feeding, without intravenous support. When hypoglycaemia remains a problem, early GH therapy should be considered 91, 92 (see following section on GH therapy). 
Recommendations
Surgery and anaesthesia
Any surgery should be carefully planned due to the increased risk of fasting hypoglycaemia in patients with SRS 93 . As a result of their diminished weight-for-height ratio, low BMI and large head, young patients with SRS are at risk of hypothermia in a cool operating room 94 . Many children with SRS also have abnormal tooth distribution and a small mandible, which affects airway visualization and intubation 95 . Finally, young children with SRS who are malnourished might not heal well following surgery 96 . [97] [98] [99] [100] [101] . The results of these clinical trials, therefore, validate the use of GH for patients with SRS.
Recommendations
Overall, clinical trials of GH treatment in patients with SGA (in which patients with SRS were included) demonstrated a satisfactory growth response and an increase in predicted adult height of 7-11 cm at pharmacological doses of GH [97] [98] [99] [100] 102 . However, the response in patients with SRS was not investigated until a Dutch longitudinal study analysed the response to GH in 62 children with a clinical diagnosis of SRS using the NH-CSS compared with 227 short, non-syndromic children born SGA. Overall, the study showed a similar response to GH in patients with SRS compared with non-SRS children born SGA (mean total height gains of 1.30 SDS and 1.26 SDS, respectively); however, the final adult height attained in patients with SRS was lower (mean adult height −2.17 SDS versus −1.65 SDS for non-SRS children born SGA) 87 . Although the mean height at the start of GH treatment in patients with SRS was statistically significantly lower than in those without SRS, it was shown that patients with all SRS subtypes benefited from GH treatment, with a trend towards increased height gain in patients with upd(7)mat or clinical SRS. In addition, some interim 100, 102 and long-term 103, 104 studies have focused on the response to GH specifically in patients with SRS, albeit without a control group of non-SRS short children born SGA. Strong predictors of the short-term and long-term responses to GH were age and height SDS at the start of GH treatment (both inversely related) [103] [104] [105] . However, the study by Rakover et al. 105 of 33 patients with SRS lacked data on adult height. Mean total height gain ranged from +1.2 to +1.4 SDS for GH doses of 35-70 μg/kg per day, which is similar to that achieved in patients with non-syndromic SGA 97, 103, 104 . In 2007, an SGA consensus statement advocated early treatment with GH for children born SGA, including those with SRS, who had severe growth retardation (height SDS ≤2.5; age 2-4 years; dose 35-70 μg/kg per day) 106 . Additional potential benefits of GH treatment are increases in appetite, lean body mass and muscle power, which can result in improved mobility 86, 107 . In patients with Prader-Willi syndrome, another imprinting disorder, GH treatment started in infancy results in increased lean body mass and motor development, as well as decreased fat mass 108, 109 ; consequently, GH treatment is now recommended from infancy in this condition. Children with SRS who are <2 years old typically present with low muscle mass and hypotonia, similarly to patients with Prader-Willi syndrome 15 , and could also benefit from early GH treatment. Further studies are necessary to investigate this option in patients with SRS.
Classic GH deficiency is neither a common nor a relevant cause of short stature in SRS, nor is it predictive of the response to GH treatment in children born SGA 103, 105, 110 . Furthermore, given the risk of hypoglycaemia associated with fasting required for GH testing, testing children with SRS might carry added risks.
For most children with SRS, an increase in height velocity of ≥3 cm per year is the lower limit of an effective response range 106 . The growth response depends on the patient's age, GH dose, height deficit, rate of weight gain and confounding problems such as intercurrent illness and scoliosis.
Levels of insulin-like growth factor 1 (IGF1) in response to GH treatment in patients with SRS are difficult to interpret. Children with 11p15 LOM have significantly higher IGF1 levels than children with upd(7) mat and other children born SGA, which suggests an element of IGF1 resistance in patients with 11p15 LOM 73, 111 . Basal serum levels of IGF1 in the upper quartile of the normal age-related range or higher can be expected in children with SRS, especially those with 11p15 LOM 73 . In children with 11p15 LOM, serum levels of insulin-like growth factor-binding protein 3 (IGFBP3) are also elevated 111 . IGF1 levels might rise significantly above the reference range in children with SRS on standard doses of GH 87, 111 . Further studies are needed to understand how best to use IGF1 and IGFBP3 serum levels to monitor GH doses in children with SRS and IGF1 resistance.
Comprehensive reviews on the use of GH in children born SGA have concluded that GH treatment seems to be safe and effective 112 . Adverse effects due to GH treatment are no more frequent in children with SRS than in those with non-syndromic SGA 87, 113 and no specific precautions are advised. Exemptions from the current SGA licensed indication used in some centres include starting GH therapy below the age of 2 years in case of: severe fasting hypoglycaemia; severe malnutrition, despite nutritional support, which will lead to gastrostomy if no improvement is seen; and severe muscular hypotonia.
Bone age advancement and puberty
The published literature on the natural history of bone age progression in patients with SRS is limited. Early bone age delay is followed by rapid advancement typically at around 8-9 years of age 3,81,113 but sometimes much younger, especially in nonvolitionally overfed children. Onset of puberty is usually within the normal range (8-13 years in girls and 9-14 years in boys) 114 but at the younger end of the spectrum 3, 73, 87, 115 . Adrenarche can be early and aggressive in comparison with children born with non-SRS SGA, particularly in those with 11p15 LOM 116 . Our experience is that in patients with SRS and early adrenarche, the onset of central puberty might be earlier and the tempo faster than expected. In the past few decades, population studies analysing the timing of normal puberty observed a mean age of puberty onset of 9.7-10.0 years in girls 114 . As a group, girls with SRS seem to start central puberty at a mean age of 9.1 years (I. Netchine, unpublished work). This early puberty further accelerates bone age maturation, which leads to an attenuated pubertal growth spurt and compromised adult height. Children with upd(7)mat are likely to progress to central puberty at an even younger age than patients with SRS and 11p15 LOM (mean starting age 8.5 years in girls and 9.5 years in boys) (I. Netchine, unpublished work). A rapid increase in BMI might also exacerbate the tendency to early adrenarche and central puberty [117] [118] [119] . The window for effective GH treatment seems to be shorter in patients with SRS than in non-SRS patients with SGA. In a study comparing a cohort of patients with SRS and a cohort of patients born SGA but without SRS, puberty started significantly earlier in the former (at 10.2 years versus 11.2 years in girls with SRS and non-SRS SGA, respectively, and at 11.4 years versus 12.0 years in boys with SRS and non-SRS SGA, respectively) 87 . Furthermore, a steeper decline in height SDS from the onset of puberty until adult height was seen in patients with SRS, which contributed to a lower adult height and a larger distance to target height than in non-SRS patients with SGA. However, in 17 patients with SRS in this study, puberty was postponed for 2 years with gonadotropin-releasing hormone analogue (GnRHa) due to a low predicted adult height. The effect of GnRHa on final height has been analysed in a cohort of patients with SGA, including patients with SRS 120, 121 . This analysis suggested that the combination of GnRHa, started at the initiation of puberty and continued for at least 2 years, along with GH treatment, improves adult height in patients born SGA with a poor adult height prognosis. A retrospective study of GnRHa treatment specifically in patients with SRS did not detect an effect of GnRHa on adult height, but this therapy was used in only 16 of 37 patients and was not standardized 104 . Further studies are required to specifically look at its effects in patients with SRS.
Aromatase catalyses the rate-limiting step in the conversion of androstenedione to oestrone and testosterone to oestradiol. In patients with adrenarche with advancing bone age, but without central puberty, third-generation aromatase inhibitors (such as anastrozole) might be helpful in preventing rapid bone maturation, but are currently not licensed for growth disorders 122 . An 18-month double-blind clinical trial is currently underway to study the efficacy and tolerance of treatment with anastrozole to slow bone maturation related to pathological adrenarche in patients with SRS and Prader-Willi syndrome 
Long-term metabolic complications
Individuals born with a low birth weight are at increased risk of adult health problems including coronary heart disease [124] [125] [126] , hypertension, dyslipidaemia, insulin resistance and obesity (the metabolic syndrome) [127] [128] [129] [130] . Studies of children born SGA indicate that those who have rapid or disproportionate catch-up in weight are at particularly high risk 119, 131, 132 . Insulin resistance in young, pre-pubertal, children with SRS can be atypical and difficult to detect in the fasting state; however, impaired glucose tolerance can be confirmed on formal oral glucose tolerance testing 133, 134 .
Insulin resistance becomes more classic in the pubertal or post-pubertal age groups with elevation in fasting levels of glucose and insulin, and possibly the development of type 2 diabetes mellitus 135, 136 . Overall, GH therapy seems to have positive metabolic effects in children born SGA 137 , but specific data on such effects in SRS are lacking. Many studies of longterm GH treatment in children born SGA have shown positive outcomes, including increased lean body mass, reduced fat mass, decreased blood pressure and an improved lipid profile 107, 120, 137, 138 , which might last after discontinuation of therapy 138, 139 . In a study of 110 children born SGA treated with GH, those with the highest baseline levels of IGF1 were the least insulin sensitive. Gains in height and IGF1 response were positively associated with insulin secretion 140 . In SRS, children with 11p15 LOM seem to be at a higher metabolic risk than children who have upd (7)mat and other children born SGA due to poor muscle mass and raised levels of IGF1 (REFS 15, 16, 73, 87) . Further research is, therefore, required on the long-term effects of GH therapy on body composition and metabolic parameters in SRS and its various genotypes. 
Recommendations
Neurocognitive problems
Motor and speech delay are common in children with SRS 4, [16] [17] [18] 20 (TABLE 2) . Motor delay might be related to reduced muscle bulk and fairly large head size. Verbal dyspraxia and more global developmental delay or learning difficulties, usually mild, have been described in some children with SRS, particularly those with upd(7) mat 12, 15, 16, 20, 141 . Autistic spectrum disorder has also been reported more frequently in this subgroup than in the other subgroups of SRS 15 . Myoclonus dystonia in patients with upd(7)mat is probably associated with altered expression of the paternally expressed SGCE on chromosome 7q21 (REFS 20, 40, 142, 143 Orthopaedic problems Orthopaedic problems seen in association with SRS include limb or body asymmetry, scoliosis, hip dysplasia and hand and/or foot anomalies (TABLE 2) . Limb asymmetry can affect the arms, legs or both. In seven patients with clinically diagnosed SRS, limb length discrepancy was not significantly affected by GH treatment 144 . Limb lengthening surgery performed to equalize limb lengths in patients with SRS has shown positive results 145 . Scoliosis has been reported in 9-36% of individuals with SRS 20, 146, 147 . The causal relationship to leg length asymmetry is not clear 146, 147 . Associated back pain has been reported inconsistently 5, 146 . GH therapy might be associated with worsening of existing scoliosis; however, causality has not been established 148 . A study in a large group of children with Prader-Willi syndrome (an imprinting disorder with clinical features that overlap with those of SRS: growth failure; infant hypotonia; early feeding difficulties; and an increased risk of scoliosis) has clearly shown that GH therapy does not influence onset and progression of scoliosis 149 ; however, specific studies are required to determine whether GH therapy modifies the risk of scoliosis in patients with SRS. Other congenital anomalies Congenital anomalies have been described in a minority of patients with SRS, particularly those with 11p15 LOM (see Supplementary information S1 (table) ). Genital abnormalities, including cryptorchidism and hypospadias, occur frequently in boys 16, 20 . MayerRokitansky-Kuster-Hauser syndrome in female patients is characterized by congenital hypoplasia or aplasia of the uterus and upper part of the vagina 16, 18, 156, 157 . Structural renal anomalies 18, 20 and congenital heart defects 4, 18, 20, 158 have also been reported. 14. 
Recommendations
Adulthood
Very little information exists in the literature regarding the long-term natural history of SRS. The majority of individuals with SRS are not routinely followed up, and the small numbers of adults reported have few medical problems. However, it is well recognized that being SGA at birth with accelerated gain in weight for length, particularly during early life, increases the risk of metabolic problems in adulthood 119, 132, 159 (see previous discussion). Medical problems reported in adult patients with 11p15 LOM include hypertension, dilated cardiomyopathy, type 2 diabetes mellitus, hypercholesterolaemia, fatty liver infiltration, elevated glucose levels and raised HbA 1c levels 135, 136, 160 ; however, these reports might not be representative of the population as a whole. 
Recommendations
Genetic counselling
Accurate genetic counselling depends on the underlying molecular cause. 11p15 LOM is associated with a low recurrence risk (with parents of a child with SRS being unlikely to have another affected child). The offspring risk is also low (meaning that individuals with SRS are unlikely to pass the condition on to their children). However, empirical figures are not available. Only three sibships with 11p15 LOM are reported in the literature 13, 20 , and the underlying mechanism is unknown in all three.
The potential for a familial trans-acting gene mutation suggests that the recurrence risk in patients with SRS and MLID could be higher than in other patients with SRS; however, evidence to support this supposition does not yet exist.
Rare familial cases of SRS have been reported with underlying mechanisms including: maternally inherited 11p15 duplication 24, 26 (see Supplementary information S2 (table)); maternally inherited CDKN1C gain-of-function mutations 60 ; and paternally inherited IGF2 loss-of-function mutations 61 . In these families, the risk of recurrence might be as high as 50% 24, 26, 60, 61 . Investigation for underlying CNVs in patients with 11p15 LOM is, therefore, important. upd(7)mat is associated with a low recurrence and offspring risk (if the karyotype of the patient is normal) 50 . Data are limited regarding the risk of parents of children with clinically diagnosed SRS having another child with SRS; however, the overall risk is probably low. Similarly, the offspring risk for individuals with clinically diagnosed SRS is likely to be low. 
Recommendation
16.1 Genetic counselling should be performed by a health professional experienced in the field of imprinting disorders. As the recurrence risk associated with CNVs is dependent on their size, location and parental origin, these should be taken into consideration during counselling for the family. (A+++)
Conclusions
Children with SRS and their families face challenges from birth to adulthood. In addition to the problems associated with being born SGA, clinicians treating patients with SRS need to be aware of syndrome-specific management issues. These include substantial feeding difficulties, severe postnatal growth failure with no catch-up, recurrent hypoglycaemia, premature adrenarche, fairly early and rapid puberty, insulin resistance, body asymmetry, orthodontic issues, sleep disordered breathing and the potential for other congenital anomalies.
Presented here are the first international consensus guidelines for the diagnosis and management of SRS, based on published evidence and expert opinion. A summary of all 72 recommendations, including a flow chart for the investigation and diagnosis of SRS, is available as supplementary information online (see Supplementary information S5).
These management recommendations apply to all patients clinically diagnosed with SRS, both with and without a molecularly confirmed diagnosis. However, identification of the underlying molecular subtype can guide treatment with regard to specific risk factors. Management should involve a multi-disciplinary approach and close parental guidance. A practical checklist for use in routine clinical follow up of these patients is proposed in TABLE 5. As published data specific to SRS are limited, many questions remain
. International collaboration and further research is urgently needed to better inform the investigation and management of patients with SRS in the future.
